Pembrolizumab - Stage IB-IV Mycosis Fungoides

Brief Summary:

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.


Website: https://clinicaltrials.gov/ct2/show/NCT03695471?term=mc1788&draw=2&rank=1


PRIMARY OBJECTIVE:

To evaluate the antitumor activity of pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy.


Sponsor:

Mayo Clinic


Collaborator:

National Cancer Institute (NCI)


Information provided by (Responsible Party):

Mayo Clinic


Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 


Please refer to this study by its ClinicalTrials.gov identifier: NCT03695471


Recruiting

Participating Locations:

Mayo Clinic - Florida
Jacksonville, FL, United States
Principal Investigator
Jason C. Sluzevich, MD
mayocliniccancerstudies@mayo.edu
855-776-0015
Recruiting
Designed and built by Giant Rabbit.